Your browser doesn't support javascript.
Omicron: a drug developer's perspective.
Fang, Fang Flora; Shi, Pei-Yong.
  • Fang FF; Abimmune Biopharma, Inc., San Diego, CA, USA.
  • Shi PY; Department of Biochemistry and Molecular Biology, Department of Biochemistry and Molecular Biology, The University of Texas Medical Branch, Galveston, TX, USA.
Emerg Microbes Infect ; 11(1): 208-211, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-1598042
ABSTRACT
We performed an annotation of 35 mutations in the spike protein of the SARS-CoV-2 Omicron variant. Our analysis of the mutations indicates that Omicron has gained prominent immune evasion and potential for enhanced transmissibility. Previous modeling study has revealed that continued evolution in both immune evasion and enhanced transmissibility by SARS-CoV-2 would compromise vaccines as tools for the pandemic control. To combat the future variants of SARS-CoV-2, the world needs novel antiviral drugs that are effective at curb viral spreading without introducing additional selective pressure towards resistant variants.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Receptors, Virus / Drug Design / Spike Glycoprotein, Coronavirus / Angiotensin-Converting Enzyme 2 / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Observational study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Emerg Microbes Infect Year: 2022 Document Type: Article Affiliation country: 22221751.2021.2023330

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Receptors, Virus / Drug Design / Spike Glycoprotein, Coronavirus / Angiotensin-Converting Enzyme 2 / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Observational study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Emerg Microbes Infect Year: 2022 Document Type: Article Affiliation country: 22221751.2021.2023330